Genitourinary Drugs Market Sales Projection, Market Statistics, Cost Structure Insights, Application, Key Trends and Global Industry Analysis By 2023

Genitourinary Drugs Market Sales Projection, Market Statistics, Cost Structure Insights, Application, Key Trends and Global Industry Analysis By 2023

“Genitourinary Drugs Market”
Genitourinary Drugs Market Analysis By Size, Share, Key Players, Trends, Insights, Dynamics, Future Outlook, Applications and Segmentation, Forecast to 2023

Genitourinary Drugs Market Size, Growth and Share Analysis By Disease (Urinary Tract Infections, Erectile Dysfunction, Hematuria), Product (Urological, Hormonal Therapy), Region and Leading Players, Forecast to 2023

The Global Genitourinary Drugs Market Size was valued USD 28,200 million in 2018 and is projected to register a CAGR of 1.65% over the assessment period (2018-2023), says Market Research Future (MRFR). The global market of genitourinary drugs may find better growth prospects with surging demand and expanding healthcare. Genitourinary drugs are expected to dominate a large part of the pharmaceuticals market. Genitourinary drugs refer to pharmaceuticals used to treat diseases of the urinary and genital organs such as kidneys, ureters, bladder, urethra, and others. The large spectrum of diseases originating from these organs drives a large market for genitourinary drugs.

Genitourinary drugs market size is expected to witness significant growth owing to rising prevalence of genitourinary diseases and expanding healthcare. According to the Centers for Disease Control and Prevention, urinary tract infections are the most common infection demanding medical care and causing almost 9.6 million ambulatory care visits. The economic burden of urinary tract infections is almost US$ 2 Bn annually. Urinary tract infections also are the leading cause of antibiotic use in the U.S.

Surging healthcare expenditure, growing world population, and growing per capita income can trigger better growth for the genitourinary drugs market. The expansion of healthcare infrastructure, including the dramatical increase in the number of hospitals and clinics, can bolster the growth of the market. The growing number of geriatrics is another driver of the market. According to the Department of Economic and Social Affairs of the U.N. almost 12.4% population in the Asian countries are more than 60-year-old.

Request Free Sample Report at: https://www.marketresearchfuture.com/sample_request/6802

Global Genitourinary Drugs Market Segmentation

Genitourinary Drugs market is segmented by Disease, Product, End User and Region

  • By Disease, the genitourinary drugs market is segmented into Urinary Incontinence & Overactive Bladder, Urinary Tract Infections, Genitourinary Cancer, Kidney/Renal Cancer, Cervical Cancer, Bladder Cancer, Interstitial Cystitis, Sexually Transmitted Diseases, Ovarian Cancer, Hematuria, Prostate Cancer, among others.
  • By Product, the genitourinary drugs market is segmented into Urological, Hormonal Therapy, Gynecological, Anti-Infectives, among others.
  • By End-use, the genitourinary drugs market is segmented into Hospitals, Clinics, Specialty Centers, and others.
  • By Regions, the genitourinary drugs market is segmented into APAC (Asia Pacific), North America, Europe, and the Middle East and Africa.

Global Genitourinary Drugs Market Regional Analysis

North America dominates the global genitourinary drugs market share with the largest market share led by the U.S. As opined by the National Kidney Foundation, urinary tract infections account for almost 10 million physician visits every year and roughly, 20% females suffer from urinary tract infections at least once during their lifetime. Factors such as the enactment of the Hospital Readmissions Reduction Program (HRRP) is expected to drive the growth of the North America market. According to the CDC, 75% of infections of the urinary tract in hospitals are associated with the use of urinary catheters.  The growing use of urinary catheters, which account for 15-25% of hospitalized patients is a large driver of the genitourinary drugs market.

The genitourinary drugs market in Europe is growing rapidly. The proliferating healthcare industry and greater rates of hospital admissions in the region are expected to boost market growth.

The Asia Pacific genitourinary drugs market is projected to become the largest market globally owing to expanding economy and per capita income. Growing pharmaceutical manufacturing and a large population drive the growth of the Asia Pacific market.

The MEA (Middle East & Africa market) is expected to account for a large growth owing to low penetration and large potential growth. However, poor economic and political conditions are hampering the growth of the market.

Global Genitourinary Drugs Market Competitive Landscape:

The genitourinary drugs market appears to be fragmented and highly competitive due to the presence of several big and small players. The market is commoditized, and major drug classes are generic. The market has also suffered a loss of exclusivity owing to patent expiration.

Thus, there is a lot of overcapacity in the market, especially in the antibiotics sector. China has a large antibiotics API manufacturing capacity which is idle resulting in large fall in prices. Many players have exited the antibiotics manufacturing which is a downside of the market.

Genitourinary Drugs Market Major Players:

Players leading the global genitourinary drugs market include Abbott, Astellas Pharma Inc., AstraZeneca, Pfizer Inc., Eli Lilly and Company, Genentech, Inc., Immunex Corp., GlaxoSmithKline plc., Ionis Pharmaceuticals, Merck & Co., Inc., Novartis AG, Bristol-Myers Squibb Company, Antares Pharma, Bayer AG, among others.

Genitourinary Drugs Industry/ Innovation/ Related News:

The Food and Drug Administration approved Recarbrio of Merck & Co., Inc., which is a combination of imipenem, cilastatin, and relebactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections. While imipenem-cilastatin, has been approved by the FDA before, relebactam, is a new beta-lactamase inhibitor antibiotic.

FDA’s under its Qualified Infectious Disease Product (QIDP) designation granted Recarbrio approval based on clinical studies. The QIDP designation is granted to antibiotic drugs used in the treatment of serious infections.

Table Of Content:

Chapter 1. Report Prologue

Chapter 2. Genitourinary Drugs Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Genitourinary Drugs Market Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Genitourinary Drugs Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Genitourinary Drugs Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

5.1.2 Bargaining Power Of Buyers

5.1.3 Threat Of New Entrants

5.1.4 Threat Of Substitutes

5.1.5 Intensity Of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Genitourinary Drugs Market, By Disease

6.1 Introduction

6.2 Urinary Tract Infections

6.3 Urinary Incontinence & Overactive Bladder

6.4 Kidney/Renal Cancer

6.5 Genitourinary Cancer

6.6 Bladder Cancer

6.7 Cervical Cancer

6.8 Interstitial Cystitis

6.9 Hematuria

6.10 Ovarian Cancer

6.11 Prostate Cancer

Chapter 7. Global Genitourinary Drugs Market, By Product

7.1 Introduction

7.2 Urological

7.3 Hormonal Therapy

7.4 Gynecological

7.5 Anti-Infectives

Chapter 8. Global Genitourinary Drugs Market, By End-User

Chapter 9. Global Genitourinary Drugs Market, By Region

TOC Continued………………

Brows More Healthcare Related Research Reports

Medical Imaging Market Size Analysis, Share | Growth and Industry Trends, 2025

Dermatology Diagnostic Devices Market Applications, Share | Size Analysis, 2022

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services.

Media Contact
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
City: Pune
State: Maharashtra
Country: India
Website: https://www.marketresearchfuture.com/reports/genitourinary-drugs-market-6802